Aclaris Therapeutics, Inc. (ACRS)
Nasdaq: ACRS · Pharmaceutical Preparations · Wayne, PA · filing with the SEC since 2012
Who owns Aclaris Therapeutics, Inc.
As filed with the SECHolders of 5% or more
6
BML Investment Partners, L.P. holds 9.9% of Common Stock, $0.00001 par value, as its SCHEDULE 13G/A filed Apr 27, 2026 says.
Directors and officers
12
report now, of 26 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
BML Investment Partners, L.P.
SCHEDULE 13G/A · filed Apr 27, 2026 · Common Stock, $0.00001 par value · 11.9% in Feb 9, 2026
Biosion, Inc.
SCHEDULE 13G/A · filed Jan 9, 2026 · Common Stock, $0.00001 par value
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.00001 par value per share · 6.3% in Apr 7, 2026
Deep Track Capital, LP
SCHEDULE 13G · filed Mar 17, 2026 · Common Stock, $0.00001 par value
Blackrock, Inc.
SCHEDULE 13G/A · filed Jan 21, 2026 · Common Stock · 5.1% in Jul 17, 2025
Frazier Life Sciences Public Fund, L.P.
SCHEDULE 13G · filed Sep 21, 2026 · Common Stock, $0.00001 par value
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed Nov 13, 2025 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 7.6% in May 12, 2025
Rock Springs Capital Management LP
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, $0.00001 par value · reported falling below 5%
Vivo Opportunity Fund Holdings, L.P.
SCHEDULE 13G/A · filed May 12, 2026 · Common Stock, $0.00001 par value · reported falling below 5%
Millennium Management LLC
SCHEDULE 13G/A · filed Jul 24, 2025 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 5.1% in May 5, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%, from 6.15% in Jul 29, 2025
What ACRS reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Confluence
A company bought · acquisition · owns, named in the 10-K filed Feb 26, 2026
2 subsidiaries in 1 country, from the list filed with the 10-K filed Feb 27, 2024.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2024 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 46 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Leonard Braden Michael | 10% owner | 1 | $1.4M | 0 | 0 | $0 |